Literature DB >> 15381789

Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis.

A Ponyi1, G Borgulya, T Constantin, A Váncsa, L Gergely, K Dankó.   

Abstract

OBJECTIVES: To present the outcome of patients with idiopathic inflammatory myositis, focusing on functional ability and quality of life.
METHODS: Analysis was performed using data from 105 adult patients with definitive polymyositis, dermatomyositis or overlap myositis, who were followed up at a single centre. The diagnosis was made between 1979 and 2000 based on Bohan and Peter's criteria. Functional ability was assessed after a minimum follow-up of 3 yr with the Health Assessment Questionnaire Disability Index (HAQDI) and quality of life was measured with the Short Form 36-item questionnaire (SF-36).
RESULTS: Fifteen patients in our cohort died and 87 participated in the evaluation of functional outcome. Functional ability after a median follow-up of 107.1 months (range 36.4-273.3) was heterogeneous. The median HAQDI score was 0.875 (range 0-2.875). Polyphasic or chronic-progressive disease course, osteoporosis and long-term follow-up were predictive of higher HAQDI scores. In terms of quality of life, significant differences from population norms were shown in all domains of the SF-36. There were no significant differences in the SF-36 scores among the patients according to clinicopathological subset or disease course.
CONCLUSIONS: Although the mortality of our cohort was favourable, myositis continues to have a great impact on life in the medium and long term. The present work indicates that myositis patients have a significantly poorer quality of life than the normal population, but there was no difference among the patients according to clinicopathological subsets.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15381789     DOI: 10.1093/rheumatology/keh404

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  36 in total

1.  Long-term follow-up of 62 patients with myositis.

Authors:  Janneke van de Vlekkert; Jessica E Hoogendijk; Marianne de Visser
Journal:  J Neurol       Date:  2014-05       Impact factor: 4.849

2.  Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand.

Authors:  Peter Szodoray; Philip Alex; Nicholas Knowlton; Michael Centola; Igor Dozmorov; Istvan Csipo; Annamaria T Nagy; Tamas Constantin; Andrea Ponyi; Britt Nakken; Katalin Danko
Journal:  Rheumatology (Oxford)       Date:  2010-06-29       Impact factor: 7.580

3.  Disability in idiopathic inflammatory myopathies: questionnaire-based study.

Authors:  Aleksandra Halina Opinc; Olga Elżbieta Brzezińska; Joanna Samanta Makowska
Journal:  Rheumatol Int       Date:  2019-04-26       Impact factor: 2.631

Review 4.  Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.

Authors:  Beatriz Y Hanaoka; Charlotte A Peterson; Craig Horbinski; Leslie J Crofford
Journal:  Nat Rev Rheumatol       Date:  2012-06-12       Impact factor: 20.543

5.  Physical impairment in patients with idiopathic inflammatory myopathies is associated with the American College of Rheumatology functional status measure.

Authors:  Beatriz Y Hanaoka; Laura C Cleary; Douglas E Long; Archana Srinivas; Kirk A Jenkins; Heather M Bush; Catherine P Starnes; Mathew Rutledge; Jidan Duan; Qian Fan; Natasha Fraser; Leslie J Crofford
Journal:  Clin Rheumatol       Date:  2014-11-12       Impact factor: 2.980

6.  Pregnancy outcome in idiopathic inflammatory myopathy.

Authors:  A Váncsa; A Ponyi; T Constantin; M Zeher; K Dankó
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

7.  Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis.

Authors:  M O Harris-Love; J A Shrader; D Koziol; N Pahlajani; M Jain; M Smith; H L Cintas; C L McGarvey; L James-Newton; A Pokrovnichka; B Moini; I Cabalar; D J Lovell; R Wesley; P H Plotz; F W Miller; J E Hicks; L G Rider
Journal:  Rheumatology (Oxford)       Date:  2008-12-11       Impact factor: 7.580

8.  Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up.

Authors:  K P Ng; F Ramos; S M Sultan; D A Isenberg
Journal:  Clin Rheumatol       Date:  2009-04-23       Impact factor: 2.980

Review 9.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

Review 10.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.